Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus BETOPTIC S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus BETOPTIC S.
BETAGAN vs BETOPTIC S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
Instill 1 drop in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Category C
Category C
Beta-Blocker
Beta-Blocker